Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the Department of Nuclear Medicine at University Hospital of Leipzig plan presentations highlighting Navidea’s PET imaging agent, NAV4694, at the German Society of Nuclear Medicine Annual Congress in Hannover, Germany, March 26-29, 2014. NAV4694 is an investigational Fluorine-18 labeled beta-amyloid imaging agent currently being evaluated in late stage clinical trials for use as an aid in differential diagnosis and to monitor progression of Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and other forms of neurodegenerative dementia.
On March 27, Osama Sabri, MD, PhD, Professor of Nuclear Medicine, Chairman and Director of the Department of Nuclear Medicine of the University of Leipzig, Germany, and President of the SNMMI Brain Imaging Council is presenting the plenary Wolfgang Becker Memorial Lecture entitled “Modern Nuclear Medical Diagnostic Methods in Dementia” in which NAV4694 images and results will be highlighted. “As the dementia field strives for earlier evaluation and treatment of cognitive impairment, it is of increasing importance to have diagnostic agents that can accurately assess patient status. Through our collaborative work with Navidea, we have been impressed with the clarity of patient diagnostic images using NAV4694 allowing easy interpretation and differentiation into amyloid-positive or amyloid-negative categories,” said Dr. Sabri. “I and my colleagues are pleased to present this information to the European nuclear medicine community.”
“We are delighted that our collaborators at the Leipzig University have shared these data with the medical community at the German Society of Nuclear Medicine. These results add to our conviction that NAV4694, with its inherent performance characteristics, may afford new opportunities to advance the early diagnosis of cognitive decline, including MCI,” said Cornelia Reininger, MD, PhD, Navidea’s Senior Vice President and Chief Medical Officer. “We remain committed to providing physicians and patients an improved PET-diagnostic agent that can aid in the differential diagnosis of Alzheimer's disease and other forms of neurodegenerative dementia.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts